Aprogen's Herceptin Biosimilar AP-063 Advances to Regulatory Approval Without Phase 3 Trials
Key Insights
Aprogen (search) received regulatory guidance from both EMA and FDA that its Herceptin biosimilar AP-063 can proceed to product approval applications without additional Phase 3 clinical trials.
The company completed Phase 1 clinical trials and submitted analytical equivalence data that satisfied regulatory requirements for biosimilar approval pathways.
This regulatory strategy provides structural benefits including reduced development costs and shortened licensing timelines in the competitive anticancer biosimilar market.
Aprogen (search) has achieved a significant regulatory milestone for its Herceptin biosimilar candidate AP-063, receiving guidance from both the European Medicines Agency (search) (EMA) and U.S. Food and Drug Administration (search) (FDA) that the product can advance to approval applications without conducting additional Phase 3 clinical trials.
Regulatory Pathway Optimization
The South Korean biotechnology company completed detailed consultations with both major global regulatory agencies on licensing strategies for AP-063. Following completion of Phase 1 clinical trials and submission of analytical equivalence data to the EMA, Aprogen (search) received confirmation that it can proceed with the product approval application process after submitting Process Performance Qualification (PPQ) data, without requiring additional confirmatory Phase 3 clinical trial data.
The EMA did recommend securing additional administration response data for healthy adults, though this was provided as a recommendation rather than a prerequisite for approval application. Similar regulatory alignment was achieved in the United States, where the FDA confirmed through pre-submission and pre-BLA meetings that approval applications could proceed based on currently secured clinical and analytical data.
Strategic Development Advantages
This regulatory pathway represents a departure from the typical biosimilar development process, which usually requires global Phase 3 clinical trials. The ability to omit confirmation clinical trials is possible when advanced analytical equivalence data and pharmacokinetic and immunogenicity data are sufficiently secured, subject to regulatory agency judgment.
A company official emphasized the strategic benefits: "The omission of phase 3 clinical trials provides structural benefits such as reducing large-scale development costs and shortening the licensing schedule. This is likely to lead to securing competitiveness in the global anticancer biosimilar market where price competition is fierce."
Manufacturing Excellence and Market Positioning
AP-063 has demonstrated manufacturing advantages through its perfusion process, with clinical substances produced via this method being recognized as independent batches by both FDA and EMA. The company has confirmed the appropriateness of the production process, high productivity, and consistency. Considering global Herceptin demand and regulatory deregulation trends, Aprogen (search) expects expanded licensing consultations around Europe and emerging countries.
Broader Pipeline Development
Beyond AP-063, Aprogen (search) is advancing multiple development programs. The company's immuno-oncology pipeline PMC-309 is undergoing Phase 1 clinical trials for solid cancer (search) in Australia, having confirmed stability at low and medium doses and entered the upper dose group. PMC-309 targets the immunosuppressive cell surface protein VISTA (search) and includes a clinical design incorporating co-administration with Merck (search)'s PD-1 (search) immunotherapy Keytruda.
Aprogen (search) secured exclusive global development and commercialization rights to PMC-309 from original developer Pamebsin (search) in August of the previous year, with expanding possibilities for global technology transfer discussions with Merck (search).
Manufacturing Infrastructure Expansion
The company is simultaneously building hybrid production infrastructure capable of performing both perfusion and fed-batch processes based on its Osong Perfusion plant. Aprogen (search) is expanding its contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) business to respond to increasing global demand for biosimilar and antibody drug production with high-production, low-cost processes and GMP-level quality control systems.
For its Humira biosimilar AP-096 (search), Aprogen (search) has completed process verification and successfully produced clinical samples using a 2000L perfusion incubator at the Osong plant, securing commercial production-level productivity.
Market Outlook
Industry observers believe that regulatory changes including biosimilar deregulation, antibody drug production capacity constraints, and expansion of combination therapies will combine with Aprogen (search)'s pipeline and production infrastructure to strengthen medium to long-term growth prospects.
Aprogen (search) plans to proceed sequentially with product license applications in Europe and the United States once PPQ-related data preparation is completed, though final approval and examination schedules may vary depending on regulatory review processes.